Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use.

ABSTRACT:

Background

In some countries including Singapore, biologic therapies are not routinely available. Instead, oral corticosteroid (OCS) is commonly used for severe asthma management, which could lead to substantial adverse health events.

Objective

To estimate the multimorbidity costs in asthma patients from a multi-ethnic Asian population.

Methods

We examined national health administrative data (2012-2019) from Singapore. Direct medical costs were summed from costs of hospitalisation, emergency department (ED), specialist care, and public primary care. Prescription data were not available but formed part of public primary care costs. We measured cost per patient-year (PY) in 2023 Singaporean dollars (SGD$1 = US$0.76 = ₤0.60 = €0.69). We performed propensity-score matchin

SUBMITTER: Lim LHM 

PROVIDER: S-EPMC12701672 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature